Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
The fund is constructive on resilient macroeconomic tailwinds and secular AI trends, but is actively shifting capital away from overvalued speculative infrastructure names into high-quality, reasonably valued 'AI adopters'.
Full Quick Take
The fund is constructive on resilient macroeconomic tailwinds and secular AI trends, but is actively shifting capital away from overvalued speculative infrastructure names into high-quality, reasonably valued 'AI adopters'.
Apis Deep Value Fund delivered an exceptional 23.2% net return in Q2 2025, powered by long positions in South Korean defense and power infrastructure. The manager remains constructive on global infrastructure, nuclear energy, and selective 'Trump Trades' while avoiding speculative areas.
Full Quick Take
Apis Deep Value Fund delivered an exceptional 23.2% net return in Q2 2025, powered by long positions in South Korean defense and power infrastructure. The manager remains constructive on global infrastructure, nuclear energy, and selective 'Trump Trades' while avoiding speculative areas.
Platinum continues to navigate a narrow market environment by avoiding overpriced US tech mega-caps in favor of mispriced global compounders. Key positioning focuses on Asian technological capabilities, Japanese power infrastructure, recovering European consumer brands, and niche biotech innovators poised for multi-year earnings outperformance.
Full Quick Take
Platinum continues to navigate a narrow market environment by avoiding overpriced US tech mega-caps in favor of mispriced global compounders. Key positioning focuses on Asian technological capabilities, Japanese power infrastructure, recovering European consumer brands, and niche biotech innovators poised for multi-year earnings outperformance.
